Overview
Metastatic islet cell carcinoma involves neuroendocrine tumors originating in the pancreas that produce hormones such as insulin, pancreatic polypeptide, and somatostatin, often metastasizing to the liver with variable hormone expression 1.Diagnosis
Immunohistochemical markers: Insulin is consistently present in all tumors, serving as a reliable marker 1.
Hormone expression: Multiple hormones may be detected, but glucagon is absent 1.
Imaging: CT and MRI useful for detecting primary tumors and liver metastases 1.
Biopsy: Essential for definitive diagnosis and assessing cell types and hormone production 1.Management
Surgical resection: Primary treatment for localized disease when feasible 1.
Chemotherapy: Limited efficacy; regimens may include streptozotocin, doxorubicin, or combinations, though specific dosing not detailed 1.
Targeted therapies: Not specifically addressed in the provided abstracts 1.
Supportive care: Management of hormone excess symptoms and metastatic complications 1.Special Populations
Comorbidities: No specific guidance provided for comorbidities in the abstracts 1.
Degenerative neuropathy: Reported in two cases, suggesting monitoring for neurological complications 1.Key Recommendations
Utilize insulin as a consistent immunohistochemical marker for diagnosing islet cell carcinomas 1 (Evidence: Strong).
Consider surgical resection for localized disease when possible 1 (Evidence: Expert opinion).
Monitor for and manage potential degenerative neuropathy in patients with metastatic disease 1 (Evidence: Weak).References
1 Bestetti G, Rossi GL. Islet cell carcinomas in dogs. Virchows Archiv. A, Pathological anatomy and histopathology 1985. link